Repligen Corp (RGEN) · Sep 8, 2026 · Acquisition

Repligen clears antitrust review for BioLife deal, but vote still looms

Antitrust clearance — HSR waiting period expired September 3; BioLife vote scheduled October 5

Repligen’s BioLife acquisition clears the HSR waiting period, removing one hurdle while leaving shareholder approval and other closing conditions outstanding.

One regulatory hurdle is cleared, but the acquisition is not closed. The HSR waiting period expired at 11:59 p.m. Eastern Time on September 3, removing the required antitrust waiting period. 〔0〕 The merger still depends on other customary conditions, including BioLife stockholder approval. (Other Events) 〔1〕

The deal economics are unchanged. Repligen continues to offer BioLife holders $11.25 in cash plus 0.1442 Repligen shares per BioLife share, terms already announced with the July 21 merger agreement. (Merger consideration)

Versus the standing expectation, this is an in-line procedural update. The acquisition itself was already disclosed, and the filing adds no revised price, closing date, synergy target, or financial outlook. Clearing HSR modestly reduces execution risk, but the key remaining catalyst is the BioLife stockholder meeting scheduled for October 5, 2026. (Other Events) 〔2〕

What to watch next

BioLife stockholder vote, October 5

Original filing on SEC EDGAR

More Repligen Corp news

Repligen clears antitrust review for BioLife deal, but vote still looms | RGEN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.